Teclistamab Alone Ups Previously Treated Myeloma Survival

by | May 31, 2026 | Health

Spread the love
In the first phase 3 trial of teclistamab monotherapy, the bispecific antibody was associated with better PFS and OS than standard regimens in relapsed or refractory multiple myeloma.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments